Our 13 protocol prespecified subgroups were time to randomization , age , sex , stroke subtype , atrial fibrillation , early ischemic change ( clinician and expert panel ) , prior antiplatelet use , stroke severity , diastolic and systolic blood pressure at randomization , center 's thrombolysis experience , and trial phase .